BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies
BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies
复制标题
DOI：
10.7150/jca.25732
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Xu, Yang
中科院分区：
文献类型：
--
作者：
Li, Shu;Wang, Zhan;Xu, Yang
BCL 6（3q27）重排是弥漫性大B细胞淋巴瘤（DLBCL）中最常见的染色体异常。以前，关于BCL 6重排与DLBCL结局之间的关系的研究仍然存在争议。在此，我们系统地回顾了文献，以确定DLBCL中BCL 6重排的预后意义。荟萃分析方法用于获得BCL 6重排与不同化疗方案治疗的DLBCL患者预后之间的关联的汇总估计。该队列共入组22项研究，涉及3037例患者。BCL 6重排被证实与总生存期（OS）呈负相关（HR=1.36，p=0.000），但与无进展生存期（PFS）无关。此外，亚组分析显示，BCL 6重排仅在用含利妥昔单抗的方案治疗的DLBCL中具有预后性。
BCL6 (3q27) rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma (DLBCL). Previously, studies on the association between BCL6 rearrangement and DLBCL outcome remain controversial. Here we systematically reviewed the literature to identify the prognostic significance of BCL6 rearrangement in DLBCL. Meta-analytic methods are used to obtain pooled estimates of the association between BCL6 rearrangement and prognosis in DLBCL patients treated with different chemotherapy regimens. A total of 22 studies are enrolled in the cohort, involving 3037 patients. BCL6 rearrangement is verified to be negatively associated with overall survival (OS) (HR=1.36, p=0.000), but not with progression-free survival (PFS). Moreover, the subgroup analyses show that BCL6 rearrangement is prognostic only in DLBCLs treated with rituximab-containing regimens.